Background: Melanoma frequently metastasizes to the lung. Improved radiologic techniques may decrease the need for biopsy of such lesions. The aim of this study was to examine factors predictive of a positive biopsy of melanoma. Methods: Using the Memorial Sloan-Kettering Cancer Center melanoma database, all patients with melanoma who had undergone biopsy of a suspicious new lung lesion from 1996 to 2009 were identified. Age, date of diagnosis, histology, and stage were obtained. Chart review was carried out to obtain medical history, smoking status, radiological appearance, and histology of lung lesions biopsied.
introduction
Outcomes for patients with metastatic malignant melanoma are generally poor; median survival ranges from 6 to 15 months [1] [2] [3] . Survival is shortest for those with nonpulmonary visceral disease (M1c) and longest for those with skin and distant lymph node involvement only (M1a). Prognosis for those with lung-only metastases (M1b) is intermediate, and for selected patients, this may be improved by surgical resection. Median survival in patients after pulmonary metastasectomy has been shown to range from 18 to 40 months with 5-year survival ranging from 22% to as high as 39% in those with a solitary pulmonary lesion [4] [5] [6] [7] [8] .
Superior survival following resection of pulmonary metastases is dependent on both careful patient selection and accurate tissue diagnosis. 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) alone or in combination with computed tomography (CT) is often used to evaluate the extent of disease before planning treatment strategies. In some studies, the use of PET has been associated with increased accuracy in the detection of metastatic lesions when compared with conventional imaging, although this increased accuracy has not been consistent across all studies, in particular when relating to small metastatic lesions [9] [10] [11] [12] [13] [14] . However, the mere presence of a new lung nodule or nodules seen on imaging is insufficient to diagnose recurrent disease, and National Comprehensive Cancer Network guidelines recommend that initial clinical recurrence should be confirmed pathologically by biopsy whenever possible [15] . The aim of this study was to examine the factors predictive of a positive lung biopsy in patients with a history of malignant melanoma presenting with new lung lesions.
methods
Following approval from the institutional review board, a search of the Memorial Sloan-Kettering Cancer Center melanoma database was carried out to identify all patients who had presented with a suspicious lung nodule or nodules and undergone a radiologically guided fine-needle biopsy or core biopsy of a suspicious lung lesion from the year 1996 to 2009. Data extracted from the melanoma database were confirmed by chart review. We recorded prior cancer diagnoses, smoking status, date of primary surgery, date of lymph node dissection if carried out, dates of first and subsequent recurrences, date of first detection of suspicious lung lesion on imaging, number and site of lesions, PET scan result if carried out, date of biopsy of lung lesion, histology of lung lesion, subsequent treatment and date of last follow-up or death. Never smokers were defined as those who had smoked <100 cigarettes in a lifetime [16] . Former smokers were those who had successfully stopped smoking for >1 year. In the case of multiple primary melanomas, the melanoma deemed most likely by clinical and pathological criteria to be related to lung metastases was used in the analysis.
All patients were staged according to the American Joint Committee on Cancer (AJCC) 2009 Staging Classification. All patients presenting with clinically suspicious lung nodules at our institution undergo biopsy for histological confirmation of metastatic disease before treatment. Patients with a diagnosis of current stage IV disease were excluded, although one patient who had stage IV melanoma resected >5 years previously was included.
Time interval to detection of lung lesions was calculated from the date of surgical resection of the primary melanoma or lymphadenectomy if carried out. For patients who underwent definitive radiation (uveal and mucosal melanoma), the date of completion of treatment was used in lieu of date of surgery. Definitive treatment of pulmonary lesions was defined as treatment with curative intent that included either surgery or definitive local treatment such as radiofrequency ablation. Survival from recurrent melanoma was calculated from the date of radiologically guided biopsy of lung nodule.
statistical methods
All patients were categorized as having metastatic melanoma, other (nonmelanoma) cancer or benign lesions based on final lung biopsy results. Comparisons of clinical characteristics across the three groups were assessed by Kruskal-Wallis tests for continuous variables and Fisher's exact test for categorical variables. To identify the clinical and pathologic features associated with metastatic melanoma on lung biopsy, polytomous response logistic regression was used. The odds ratios (ORs) for melanoma-positive biopsy versus other cancers (lung or other primary) and melanoma-positive biopsy versus benign lung lesions are presented for each variable. Variables with an overall P value <0.2 on univariate analysis were evaluated by multivariable analysis. A stepwise selection was carried out and only variables with an overall P value <0.05 were retained in the final model.
Median overall survival from the date of definitive histological diagnosis on lung biopsy was estimated by Kaplan-Meier methods. Due to timevarying start dates of treatment of stage IV disease, the effect of undergoing local treatment on overall survival was analyzed as a time-dependent variable in a Cox regression model, adjusting for clinical covariates including multiplicity of lung lesions, interval from primary diagnosis until development of metastases, and age at diagnosis of lung lesion.
results

patient characteristics
A total of 229 patients with a prior history of melanoma underwent radiologically guided biopsy of a suspicious lung lesion from 1996 to 2009. Median age at detection of the lung lesion was 67 years (range 20-92 years) ( Table 1) . Sixty-one patients (27%) had a prior invasive nonmelanoma cancer (Table 2 ). Forty eight percent of the patients were lifelong nonsmokers, 8% were current smokers, 43% were former smokers, and 1% had unknown smoking status.
primary melanoma characteristics
The characteristics of the primary melanomas are shown in Table 1 ; 25 (11%) had multiple prior melanomas. Melanoma stage at detection of the lung lesion is shown in Table 1 . Fifty-six percent of patients had localized disease (stage 0/I/II) before the development of lung nodules. Five patients had active in-transit or recurrent nodal disease at the time of detection of lung nodules. Twenty-five patients were discovered to have a lung nodule at the time of diagnosis of their primary melanoma.
characteristics of lung lesions detected
Sixty-seven (29%) patients had solitary lung nodules; 162 (71%) had multiple nodules, of which 139 (86%) were bilateral (Table 3 ). In addition to lung nodule(s), 40 patients (18%) had sites of nonpulmonary visceral metastases detected, 25 patients (11%) had extrathoracic lymphadenopathy, 8 (4%) had original articles Annals of Oncology additional soft tissue disease only, and 22 (10%) had a combination of these. Two hundred and two (88%) biopsies were positive for malignancy: 159 (69%) were metastatic melanoma, 31 (14%) were new primary non-small-cell lung cancer (NSCLC), and 12 (5%) were recurrent metastatic nonmelanoma cancer. Twenty-seven biopsies (12%) were benign (Table 4 ). There were eight (3%) false-negative biopsies: seven cases of melanoma and one of metastatic leiomyosarcoma. These were all diagnosed on re-biopsy (six) or upon development of extrapulmonary metastatic disease. There were no false-positive biopsies.
Median interval from primary melanoma to histological diagnosis of recurrent melanoma was 36 months (range 0.3-396). For biopsies that showed a nonmelanoma cancer median interval to detection was 24 months and that for a benign lesion was 58 months. There was a borderline significant difference between these by Kruskal-Wallis test (P = 0.05), suggesting that nodules detected later were more likely to be benign. Patients with a diagnosis of metastatic melanoma had a deeper median Breslow depth of 2.5 mm and a higher median mitotic rate (>5 mm 2 ) than those with benign or nonmelanoma lesions.
Patients with a diagnosis of recurrent melanoma on lung biopsy were more likely to have multiple nodules on imaging (Table 3) . Of the 67 solitary pulmonary nodules biopsied, 75% (50) were malignant, and only 45% (30) were melanoma. One hundred and sixty-two patients with multiple lung lesions were biopsied; of these, 93% (152) were malignant, 80% (129) of which were melanoma. Thirty-nine of the 40 patients with nonpulmonary visceral metastases had metastatic melanoma on lung biopsy. Twenty-five patients had a lung nodule(s) detected concurrently with a primary melanoma. Only 8 of these (32%) were melanoma, 10 (40%) were primary lung cancers, 5 (20%) were benign, and 2 (8%) were recurrent nonmelanoma cancers.
One hundred and thirteen (49%) patients underwent PET scan before biopsy; 89 (80%) of these lesions demonstrated abnormal FDG uptake. The proportion of FDG-avid lesions was not statistically different between patients diagnosed with melanoma, nonmelanoma cancer, or benign lesions (P = 0.54) ( Table 3 ). The sensitivity of PET for detection of malignancy was 81% [95% confidence interval (CI) 71% to 88%] with a specificity of 32% (95% CI 13% to 57%).
univariate and multivariable analysis
On univariate analysis, eight variables were significantly associated with metastatic melanoma on biopsy (supplemental Table S1 , available at Annals of Oncology online). These were AJCC stage before detection of lung nodules (P < 0.001), smoking history (P = 0.002), prior nonmelanoma cancer (P < 0.001), multiplicity of lung nodules on CT (P < 0.001), ulceration (P = 0.05), regression (P = 0.04), age at detection of the lung lesion (P = 0.05), and nonpulmonary visceral metastases (P < 0.001).
On multivariable analysis, four of these variables remained associated with a diagnosis of melanoma on biopsy (Table 5) . Patients with a more advanced stage of melanoma before detection of lung nodules had higher odds of metastatic melanoma being present on biopsy. Compared with never smokers, patients with a smoking history had five times lower odds of having melanoma than other cancers, OR 0.21 (95% CI 0.08-0.53). Similarly, those with a history of a prior nonmelanoma cancer had four times lower odds than those without prior nonmelanoma cancer of having melanoma present on biopsy versus an alternate cancer diagnosis, OR 0.26 (95% CI 0.26-0.59). Compared with solitary nodules, patients with multiple nodules had almost four times higher odds of having a melanoma diagnosed versus a nonmelanoma cancer, OR 3.44 (95% CI 1.49-7.93) and five times higher odds of having a melanoma versus a benign nodule, OR 5.58 (95% CI 2.21-14.06).
survival and surgical resection
In patients whose lung biopsy showed metastatic melanoma, the estimated median overall survival from the date of lung biopsy was 12 months (95% CI 9.1-13.5) (Figure 1 ). The estimated 2-year survival for patients with metastatic melanoma was 21% (95% CI 14% to 28%). Patients whose biopsy showed a nonmelanoma cancer had a median survival of 40 months (95% CI 20.5-62.5). The estimated median survival for patients diagnosed with a new primary lung cancer was 40 months (95% CI 20.7-62.5) and that for recurrent nonmelanoma cancer was 42 months (95% CI 2 to not 
discussion
This large retrospective study highlights the importance of tissue diagnosis of lung nodules occurring in patients with a history of malignant melanoma. As histological confirmation of metastases is the standard of care at our institution and almost all patients are amenable to biopsy, this represents the majority of patients presenting with potentially metastatic lung nodules. In this group of patients, 12% of lung lesions were benign on biopsy, and although the majority (88%) of lesions biopsied were malignant, only 69% were melanoma. There was a high incidence of nonmelanoma cancer detected. Fourteen percent of patients had a new potentially curable primary lung cancer, underscoring the need to make an accurate diagnosis.
In clinical situations in which one would expect a diagnosis of melanoma, another diagnosis was made in 31% of cases. When a new diagnosis of melanoma and lung lesions occurred concurrently, metastatic melanoma was present in the lung in only 32% of cases. It is not only crucial to distinguish benign from malignant disease but also necessary to establish a definitive histological diagnosis before initiation of therapy.
Our results are consistent with a smaller study by Meyerson et al. [17] who previously demonstrated a 83.2% incidence of malignant diagnoses in patients with a history of malignancy and a new lung nodule once patients with coccidioidomycosis, a fungal lung infection endemic in the area in question, were excluded. That study, however, reviewed only 95 patients with a variety of malignancies, whereas our study is larger, melanoma specific, and not complicated by location-specific comorbidities.
In our dataset, there were a surprisingly high number of patients (27%) who had another primary nonmelanoma cancer. There are a number of potential explanations for this. Survivors of cutaneous melanoma are at higher risk than the general population of certain second primary malignancies [18] [19] [20] [21] . Previous investigators have demonstrated an increase in the rates of second malignancies of between 28% and 32% for patients with a history of prior melanoma [19, 20] . Although our figure of 27% is higher than that previously reported for second primary malignancies following a diagnosis of melanoma, prior epidemiological studies followed patients only after diagnosis, whereas our study included all cancers occurring both before and after the diagnosis of melanoma until their presentation with a suspicious lung lesion [22] [23] [24] . Conversely, patients with a history of breast and prostate cancer and those with nonHodgkin lymphoma are at increased risk of developing subsequent melanoma [22] [23] [24] . These diagnoses represent over half of the patients in our study with a prior nonmelanoma cancer. Lastly, our study population is gathered from a large cancer center and referral bias may lead to enrichment for patients with two or more malignancies. This is emphasized by the fact that of the 61 patients who had an additional nonmelanoma cancer, 14 (23%) had three primary malignancies.
On multivariable analysis, four variables were significantly associated with a metastatic melanoma diagnosis. These were stage II or greater melanoma, nonsmoking status (melanoma versus other only), no prior malignancy, and the presence of multiple nodules. Using these four factors, it was possible to stratify patients as to the risk of metastatic melanoma being present on biopsy (supplemental Table S2 , available at Annals of Oncology online). For example, of the 53 patients who had all four variables associated with the presence of melanoma, 50 (94%) had melanoma; the remaining 6% were benign lesions. In contrast, for those who had one or fewer predictive variables original articles
Annals of Oncology present, the risk of melanoma being diagnosed on biopsy was <30%. This underscores the requirement for biopsy in patients presenting with new lung lesions-in particular those with few of the variables present associated with a higher risk of melanoma diagnosis on biopsy, in order to avoid missing potentially curable cases of primary lung cancer or overtreatment of benign conditions. Although FDG-PET is often used in the staging of malignant melanoma, in our study, PET added little to the diagnosis of lung lesion. With the caveats applying to a retrospective dataset and possible selection bias, proportions of patients with melanoma, nonmelanoma cancer, and benign conditions did not differ in FDG avidity on PET. In a recently published meta-analysis, both FDG-PET and PET-CT were shown to be more sensitive and specific than CT for the primary staging of melanoma metastases [25] . However, our study is composed largely of patients with low-volume lungonly metastases and PET appears to be less accurate in this scenario than at other metastatic sites [9, 11] . Fuster et al. [9] in a study of 115 patients with suspected recurrent melanoma showed PET to have a sensitivity of only 57% for the detection of lung metastases with false-negative and false-positive rates of 11.8% and 5.0%, respectively. In a similar patient group, Strobel et al. [11] showed that PET had a false-negative rate of 13%, over half of which were small lung metastases. This underlines the importance of context when applying the results of such a meta-analysis. Within our study, it is possible that the patient group selected for FDG-PET differed from the group as a whole, and we do not know what the utility of FDG-PET would be in the entire patient group. However, based on our findings, PET may be more useful to rule out the presence of nonpulmonary occult metastatic disease before proceeding with potentially curative surgery and does not appear to be a reliable way to evaluate lung nodules in patients such as those in this cohort.
Considered as a group, the 159 patients whose biopsies showed metastatic melanoma in the lung had a median survival of 12 months. This is the expected median survival for patients with stage IV M1b melanoma [1] . Twenty patients (13%) underwent surgical resection with curative intent in our cohort. At the time of writing, 20% of these patients remained free of disease. This is consistent with previously published series in resected metastatic malignant melanoma [4, 8, 26] . Although this is clearly a select group and a retrospective study, Cox regression analysis adjusted for the important clinical covariates of age, disease-free interval, and the presence of single or multiple lung lesions demonstrated a HR for survival for patients undergoing surgery of 0.49 (95% CI 0.29-0.83, P = 0.008). Therefore, despite the fact that the majority of those who undergo surgery with curative intent will eventually recur, a significant survival benefit is still seen in this group. However, it is still possible that this improvement is due entirely to selection bias. This question is currently under investigation as part of an ongoing randomized trial (NCT01013623). Over 50% of those who had a new primary NSCLC detected were stage IA or IB at the time of subsequent surgical resection, which may have contributed to the above average survival of patients with NSCLC in our study.
Our study highlights the importance of tissue diagnosis before decision making regarding treatment for these patients. We demonstrate a subset of patients who are unlikely to have a diagnosis of metastatic melanoma when presenting with a new lung nodule. Furthermore, most nodules detected at the time of initial diagnosis of a primary melanoma were not metastatic melanoma. To achieve optimal outcomes for this patient group, careful patient selection for treatment with histological confirmation of metastases is mandated. 
